PENNSYLVANIA, October 13 - muscles in the face, trunk and extremities; and

WHEREAS, In some cases, people may experience movement of the

arms, legs, fingers, and toes; and

WHEREAS, In some case, TD may affect the tongue, lips and

jaw; and

WHEREAS, In other cases, symptoms may include swaying

movements of the trunk or hips and may impact the muscles

associated with walking, speech, eating and breathing; and

WHEREAS, TD can develop months, years or decades after a

person starts taking DRBAs and even after they have discontinued

use of those medications; and

WHEREAS, Not everyone who takes a DRBA develops TD, but if it

develops it is often permanent; and

WHEREAS, Common risk factors for TD include advanced age and

alcoholism or other substance abuse disorders; and

WHEREAS, Postmenopausal women and people with a mood disorder

are also higher risk of developing TD; and

WHEREAS, A person is at higher risk for TD after taking DRBAs

for three months or longer, but the longer the person is on

these medications, the higher the risk of developing TD; and

WHEREAS, Studies suggest that overall risk of developing TD

is between 10% and 30%; and

WHEREAS, It is estimated that more than 500,000 Americans

suffer from TD; and

WHEREAS, According to the National Alliance for Mental

Illness, one in every four patients receiving long-term

treatment with an antipsychotic medication will experience TD;

and

WHEREAS, Years of difficult and challenging research have

resulted in recent scientific breakthroughs, with two new

20210SR0095PN0679 - 2 -

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30